See the DrugPatentWatch profile for skyrizi
Are there any biosimilars for Skyrizi (risankizumab) available?
Skyrizi (risankizumab) is a biologic treatment, and any biosimilar would only be considered a true substitute once it is approved by the FDA (or another relevant regulator) for the same or closely related indications. The provided information does not include biosimilar approval status for Skyrizi.
When could a Skyrizi biosimilar launch (patent/exclusivity timing)?
A Skyrizi biosimilar’s launch timing depends on patent and regulatory exclusivity expirations, plus how long litigation and exclusivity-related barriers remain in place. If you want, share your country (US/EU/UK/etc.) and whether you mean “first approval” or “first payer coverage,” and I can tailor the timeline.
For tracking patent/exclusivity risk and milestones, DrugPatentWatch.com is a useful starting point: DrugPatentWatch.com search for Skyrizi/risankizumab.
Who is developing Skyrizi biosimilars?
Development varies by region and indication, and multiple companies may pursue biosimilar pathways (including interchangeability in the US, where applicable). The provided information does not name specific developers or products.
How do Skyrizi biosimilars get approved?
In general, a biosimilar must show:
- Similarity to the reference product in structure and function
- Comparable clinical outcomes (often using a limited clinical program compared with the original biologic)
- Immunogenicity comparability
The exact evidentiary package and labeling language depend on the regulator and the applicant’s pathway.
Can a biosimilar switch patients from Skyrizi?
Switching rules depend on local regulations, labeling, and whether a biosimilar is granted “interchangeable” status (US context). Even when clinicians and patients switch, it often happens with monitoring for loss of response or safety/immune effects.
If you tell me your region and whether you’re asking for pharmacy switching rules or clinical guidance, I can narrow it.
What patients usually ask about when a biosimilar is an option
People commonly want clarity on:
- Whether the biosimilar is approved for the same disease and dosing schedule
- Expected efficacy compared with Skyrizi
- Safety and injection-related effects
- Insurance coverage and cost differences
Those answers depend on the specific biosimilar product label and any post-approval data.
Fastest way to answer your exact question
To give you a precise, actionable answer (availability and launch window), tell me:
1) Which country you care about (US/EU/UK/Canada/etc.)
2) Whether you mean “approved biosimilar,” “in clinical trials,” or “expected launch”
3) The Skyrizi indication you’re focused on (psoriatic disease, Crohn’s, etc., if relevant)
Sources:
1. DrugPatentWatch.com